Concert Pharmaceuticals Inc. (NASDAQ:CNCE) fell 4.3% on Friday . The stock traded as low as $10.11 and last traded at $10.17, with a volume of 70,511 shares traded. The stock had previously closed at $10.63.

CNCE has been the topic of several recent analyst reports. Brean Capital reiterated a “buy” rating on shares of Concert Pharmaceuticals in a research note on Saturday, April 30th. Zacks Investment Research upgraded Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Finally, Stifel Nicolaus initiated coverage on Concert Pharmaceuticals in a research note on Friday, July 1st. They issued a “buy” rating and a $23.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $26.43.

The stock’s 50 day moving average is $11.44 and its 200 day moving average is $12.52. The stock’s market cap is $225.38 million.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.03. On average, equities analysts expect that Concert Pharmaceuticals Inc. will post ($2.51) EPS for the current fiscal year.

An institutional investor recently raised its position in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP increased its stake in shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned 1.02% of Concert Pharmaceuticals worth $4,256,000 at the end of the most recent reporting period.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.